Your browser is no longer supported. Please, upgrade your browser.
Settings
ELOX [NASD]
Eloxx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.73 Insider Own0.10% Shs Outstand40.18M Perf Week-3.65%
Market Cap117.99M Forward P/E- EPS next Y-0.55 Insider Trans- Shs Float34.71M Perf Month-33.67%
Income-29.30M PEG- EPS next Q-0.14 Inst Own25.20% Short Float4.89% Perf Quarter-39.45%
Sales- P/S- EPS this Y35.50% Inst Trans3.22% Short Ratio0.76 Perf Half Y-61.63%
Book/sh0.07 P/B18.86 EPS next Y5.20% ROA-98.00% Target Price- Perf Year-53.52%
Cash/sh- P/C- EPS next 5Y- ROE-242.60% 52W Range1.25 - 6.77 Perf YTD-66.83%
Dividend- P/FCF- EPS past 5Y36.40% ROI- 52W High-80.50% Beta2.49
Dividend %- Quick Ratio1.60 Sales past 5Y- Gross Margin- 52W Low5.18% ATR0.12
Employees25 Current Ratio1.60 Sales Q/Q- Oper. Margin- RSI (14)35.54 Volatility5.80% 8.61%
OptionableYes Debt/Eq3.75 EPS Q/Q37.80% Profit Margin- Rel Volume0.17 Prev Close1.37
ShortableYes LT Debt/Eq1.75 Earnings- Payout- Avg Volume2.22M Price1.32
Recom2.30 SMA20-15.09% SMA50-22.64% SMA200-53.57% Volume385,303 Change-3.65%
Jun-30-21Initiated Mizuho Buy $3.10
May-27-21Initiated B. Riley Securities Buy $5
Jun-11-20Downgrade Citigroup Buy → Neutral
Sep-06-19Initiated Janney Buy $14
Dec-24-18Initiated H.C. Wainwright Neutral $10
Jul-03-18Initiated Citigroup Buy
Jul-12-21 02:37AM  
Jul-07-21 08:04AM  
Jul-06-21 04:15PM  
May-27-21 08:30AM  
May-21-21 08:52AM  
May-19-21 08:46AM  
May-18-21 02:15PM  
May-14-21 07:00AM  
May-13-21 04:01PM  
May-06-21 05:15PM  
Apr-29-21 04:15PM  
Apr-20-21 07:48AM  
Apr-05-21 10:02AM  
Apr-01-21 09:08AM  
07:45AM  
Mar-12-21 12:30AM  
Mar-11-21 04:01PM  
02:30PM  
Mar-04-21 05:14PM  
Feb-09-21 07:00AM  
Jan-26-21 07:00AM  
Jan-20-21 07:00AM  
Jan-13-21 09:00AM  
01:31AM  
Dec-16-20 08:36AM  
Nov-18-20 11:30AM  
Nov-09-20 08:00AM  
Nov-06-20 09:31AM  
Nov-05-20 04:01PM  
02:30PM  
Oct-27-20 07:30AM  
Oct-22-20 08:57AM  
Oct-15-20 07:00AM  
Sep-14-20 10:06AM  
Aug-26-20 07:30AM  
Aug-12-20 07:30AM  
Aug-06-20 07:30AM  
Aug-04-20 07:30AM  
Jul-28-20 12:33PM  
Jul-21-20 02:17PM  
Jul-17-20 12:37PM  
Jul-15-20 01:08PM  
Jun-18-20 11:14AM  
10:42AM  
Jun-17-20 04:01PM  
Jun-11-20 12:06PM  
May-27-20 12:48PM  
May-08-20 03:01PM  
May-07-20 04:01PM  
Apr-21-20 12:37PM  
Apr-20-20 09:24AM  
Apr-13-20 07:30AM  
Apr-06-20 10:53AM  
Mar-25-20 09:00AM  
Mar-10-20 01:45PM  
Mar-05-20 04:00PM  
02:30PM  
Feb-26-20 04:00PM  
Jan-14-20 02:30PM  
Dec-27-19 06:38AM  
Dec-24-19 07:45AM  
Dec-22-19 06:41PM  
Dec-18-19 07:00AM  
Dec-11-19 05:09PM  
Dec-06-19 07:43AM  
Nov-19-19 07:00AM  
Nov-18-19 07:00AM  
Nov-07-19 10:00AM  
Nov-05-19 04:01PM  
Oct-31-19 12:15PM  
Oct-23-19 12:18PM  
Oct-10-19 08:41AM  
Sep-23-19 07:30AM  
Sep-16-19 07:30AM  
Sep-13-19 07:48PM  
Sep-10-19 07:30AM  
Aug-26-19 09:30AM  
Aug-13-19 10:01AM  
Aug-08-19 12:51PM  
Aug-07-19 07:30AM  
Aug-05-19 08:00AM  
Jul-31-19 12:12PM  
Jul-17-19 07:30AM  
Jun-24-19 04:01PM  
Jun-20-19 08:36AM  
07:25AM  
Jun-19-19 04:01PM  
Jun-10-19 08:00AM  
Jun-06-19 04:27PM  
01:34PM  
12:30PM  
May-27-19 11:10AM  
May-21-19 12:50PM  
May-19-19 09:29PM  
May-09-19 02:50PM  
07:00AM  
May-02-19 10:30AM  
Apr-22-19 09:37AM  
Apr-15-19 01:15PM  
Apr-11-19 02:45PM  
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Belloff Neil S.COO, GENERAL COUNSEL &CORP SECJul 30Option Exercise0.001,563033,158Jul 30 08:32 PM
Belloff Neil S.COO, GENERAL COUNSEL &CORP SECMay 25Option Exercise0.006,250033,430May 26 04:10 PM
PAREKH RAJESH BDirectorMay 13Buy1.352,466,6663,329,9994,827,129May 17 09:22 AM
Pontifax Management 4 G.P. (2010% OwnerMay 13Buy1.355,925,9257,999,9993,679,797May 17 07:03 AM
Nussbaum RanDirectorMay 13Buy1.355,925,9257,999,9993,679,797May 17 07:02 AM
Kariv TomerDirectorMay 13Buy1.355,925,9257,999,9993,679,797May 17 07:00 AM
Belloff Neil S.COO, GENERAL COUNSEL &CORP SECApr 30Option Exercise0.001,562027,639May 03 10:15 AM
Williams Gregory C.CHIEF EXECUTIVE OFFICERFeb 25Option Exercise0.0050,000059,989Feb 26 07:05 PM
Belloff Neil S.COO, GENERAL COUNSEL &CORP SECFeb 25Option Exercise0.0025,000033,415Feb 26 07:05 PM
Belloff Neil S.COO, GENERAL COUNSEL &CORP SECJan 30Option Exercise0.001,56308,957Feb 02 04:10 PM
Williams Gregory C.CHIEF EXECUTIVE OFFICERJan 30Option Exercise0.001,875010,632Feb 02 04:10 PM
Belloff Neil S.COO, GENERAL COUNSEL &CORP SECOct 30Option Exercise0.001,56207,853Nov 02 04:20 PM
Williams Gregory C.CHIEF EXECUTIVE OFFICEROct 30Option Exercise0.001,87509,382Nov 02 04:20 PM